Search results for "cobalamin"

showing 5 items of 15 documents

Investigation on a MMACHC mutant from cblC disease: The c.394C>T variant

2022

The cblC disease is an inborn disorder of the vitamin B12 (cobalamin, Cbl) metabolism characterized by methylmalonic aciduria and homocystinuria. The clinical consequences of this disease are devastating and, even when early treated with current therapies, the affected children manifest symptoms involving vision, growth, and learning. The illness is caused by mutations in the gene codifying for MMACHC, a 282aa protein that transports and transforms the different Cbl forms. Here we present data on the structural properties of the truncated protein p.R132X resulting from the c.394C > T mutation that, along with c.271dupA and c.331C > T, is among the most common mutations in cblC. Althou…

Vitamin B12 (cobalamin)Structure-function relationshipBiophysicsBiochemistryAnalytical ChemistryVitamin B 12MutationMMACHC proteinHumansMethylmalonic aciduria and homocystinuria cblC typeHomocystinuriaCarrier ProteinsChildOxidoreductasesAmino Acid Metabolism Inborn ErrorsMolecular BiologyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics
researchProduct

Cyanocobalamin Ultraflexible Lipid Vesicles: Characterization and In Vitro Evaluation of Drug-Skin Depth Profiles

2021

Atopic dermatitis (AD) and psoriasis are the most common chronic inflammatory skin disorders, which importantly affect the quality of life of patients who suffer them. Among other causes, nitric oxide has been reported as part of the triggering factors in the pathogenesis of both conditions. Cyanocobalamin (vitamin B12) has shown efficacy as a nitric oxide scavenger and some clinical trials have given positive outcomes in its use for treating skin pathologies. Passive skin diffusion is possible only for drugs with low molecular weights and intermediate lipophilicity. Unfortunately, the molecular weight and hydrophilicity of vitamin B12 do not predict its effective diffusion through the skin…

Drugliposomesmedia_common.quotation_subjectPharmaceutical Sciencelcsh:RS1-441Dermatitis02 engineering and technologyPharmacology030226 pharmacology & pharmacyArticleNitric oxidelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePsoriasismedicineCyanocobalaminVitamin B12cyanocobalaminskin topical deliverymedia_commonLiposomeatopic dermatitisVesiclePellAtopic dermatitisvitamin B12psoriasis021001 nanoscience & nanotechnologymedicine.diseaselipid vesicleschemistrytransferosomes0210 nano-technologyTecnologia farmacèuticaPharmaceutics
researchProduct

Higher vitamin B12 levels in neurodevelopmental disorders than in healthy controls and schizophrenia

2020

Recent studies suggest that both high and low levels of vitamin B12 (vitB12) may have negative health impacts. We measured VitB12 in patients with the Neurodevelopmental disorders (ND) (n = 222), comprised of Autism Spectrum Disorders, specific Developmental disorders, and Intellectual Disability (aged 2-53 years), schizophrenia (n = 401), and healthy controls (HC) (n = 483). Age-and gender-adjusted vitB12 z-scores were calculated by comparisons with a reference population (n = 76 148). We found higher vitB12 in ND (median 420 pmol/L, mean z-score: 0.30) than in HC (316 pmol/L, z-score: 0.06, P < .01) and schizophrenia (306 pmol/L, z-score: -0.02, P < .001), which was significant after adju…

AdultMale0301 basic medicinemedicine.medical_specialtyAdolescentRenal functionBiochemistryCobalaminHemoglobinsYoung Adult03 medical and health scienceschemistry.chemical_compoundFolic Acid0302 clinical medicineInternal medicineIntellectual disabilityLeukocytesGeneticsHumansMedicineIn patientVitamin B12ChildMolecular Biologybusiness.industryVitamin B 12 DeficiencyMiddle Agedmedicine.diseaseVitamin B 12030104 developmental biologyEndocrinologychemistryNeurodevelopmental DisordersSchizophreniaCase-Control StudiesChild PreschoolDietary SupplementsSchizophreniaAutismFemaleHemoglobinbusiness030217 neurology & neurosurgeryBiotechnologyThe FASEB Journal
researchProduct

Early Biochemical and Hematological Response to Intramuscular Cyanocobalamin Therapy in Vitamin B&lt;sub&gt;12&lt;/sub&gt;-Deficient Patients

2013

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Data on early biochemical and hematological responses to cobalamin therapy in vitamin B&lt;sub&gt;12&lt;/sub&gt;-deficient patients are scarce. Therefore, we investigated whether cobalamin injections would include prompt biochemical and hematological responses in vitamin B&lt;sub&gt;12&lt;/sub&gt;-deficient patients. &lt;b&gt;&lt;i&gt;Subjects and Methods:&lt;/i&gt;&lt;/b&gt; Seven female patients (mean age: 69.4 years, range: 61-78) with a mean serum cobalamin level of 104 ± 38 pmol/l mean ± SD and 7 male patients (mean age: 67.0 years, range: 53-78) with a mean serum cobalamin level of 84 ± 40 (±SD) participated in the study. They were adm…

Vitamin bVitaminNutrition and Dieteticsintegumentary systemMethionine metabolismErythrocyte indicesMethylmalonic acidnutritional and metabolic diseasesMedicine (miscellaneous)PhysiologyHematological responsePharmacologyCobalaminchemistry.chemical_compoundchemistryhemic and lymphatic diseasespolycyclic compoundsheterocyclic compoundsCyanocobalaminAnnals of Nutrition and Metabolism
researchProduct

MTHFR 677C → T genotype modulates the effect of a 5-year supplementation with B-vitamins on homocysteine concentration: The SU.FOL.OM3 randomized con…

2018

Aims To study how MTHFR 677C→T genotype modulates the effect of supplementation with B-vitamins on total homocysteine (tHcy) and B-vitamin concentrations. Methods 2381 patients with a personal history of cardiovascular disease were randomly assigned to one of four groups: 1) B-vitamins alone (560 μg of 5-methyl-THF, 3 mg of vitamin B6 and 20 μg of vitamin B12), 2) n-3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio), 3) B-vitamins and n-3 fatty acids, and 4) placebo. Participants were followed up for 4.7 years. At baseline and annually thereafter, biological parameters were assessed. Multivariate and linear mixed models were fit to study the interaction between B-vitamins and MTHFR …

B VitaminsMaleHomocysteinePhysiologylcsh:Medicine[SDV.GEN] Life Sciences [q-bio]/Genetics030204 cardiovascular system & hematologyBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicineBlood plasmaGenotypeMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceHomocysteine[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMultidisciplinarybiologyOrganic CompoundsFatty AcidsPyridoxineVitaminsMiddle AgedLipidsBody Fluids3. Good healthChemistryBloodCardiovascular DiseasesCreatininePhysical SciencesVitamin B ComplexFemaleAnatomyResearch Articlemedicine.medical_specialtyGenotypePlaceboBlood PlasmaCobalamins03 medical and health sciencesFolic AcidDouble-Blind MethodInternal medicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyVitamin B12Methylenetetrahydrofolate Reductase (NADPH2)[SDV.GEN]Life Sciences [q-bio]/GeneticsCreatininePolymorphism Geneticbusiness.industryOrganic Chemistrylcsh:RChemical CompoundsBiology and Life Sciences[SDV.AEN] Life Sciences [q-bio]/Food and NutritionB vitaminschemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMethylenetetrahydrofolate reductaseDietary Supplementsbiology.protein[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologielcsh:Qbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPLoS ONE
researchProduct